» Articles » PMID: 36143062

FGFR-2 and Epithelial-Mesenchymal Transition in Endometrial Cancer

Overview
Journal J Clin Med
Specialty General Medicine
Date 2022 Sep 23
PMID 36143062
Authors
Affiliations
Soon will be listed here.
Abstract

Background: At present, EC staging is based on the WHO conservative criteria, which only consider the percentage of gland formation. The molecular subgrouping of EC recently proposed by the Cancer Genome Atlas (TCGA) represents a milestone in precise molecular-based patient triage. The present study aimed to investigate the influence of FGFR-2 on the epithelial-mesenchymal transition (EMT) and whether it can lead to endometrial cancer dedifferentiation.

Methods: One hundred and three White female patients with confirmed EC were enrolled in our research. For the analysis, we performed next-generation sequencing and immunohistochemical analyses of E-cadherin, β-catenin, and vimentin.

Results: Tumor grade progression was closely correlated with LVI ( = 0.0338), expression of vimentin ( = 0.000), tumor budding ( = 0.000), and lack of E-cadherin ( = 0.0028). Similar observations were noted with regard to TNM/FIGO stage progression. In terms of FGFR-2 mutation, we found the following correlation -values: LVI ( = 0.069), expression of vimentin ( = 0.000), tumor budding ( = 0.000), and lack of E-cadherin ( = 0.000), RFS ( = 0.032), ECSS ( = 0.047).

Conclusions: FGFR-2 is the important factor influencing on EMT.

Citing Articles

Lower mRNA Expression and Higher Levels of in HER2-Positive Breast Cancer.

Dix-Peek T, Dickens C, Valcarcel J, Duarte R Biology (Basel). 2024; 13(11).

PMID: 39596875 PMC: 11591975. DOI: 10.3390/biology13110920.


Modelling the complex nature of the tumor microenvironment: 3D tumor spheroids as an evolving tool.

Rodrigues D, Reis R, Pirraco R J Biomed Sci. 2024; 31(1):13.

PMID: 38254117 PMC: 10804490. DOI: 10.1186/s12929-024-00997-9.


The impact of poor metabolic health on aggressive breast cancer: adipose tissue and tumor metabolism.

Sankofi B, Valencia-Rincon E, Sekhri M, Ponton-Almodovar A, Bernard J, Wellberg E Front Endocrinol (Lausanne). 2023; 14:1217875.

PMID: 37800138 PMC: 10548218. DOI: 10.3389/fendo.2023.1217875.


Independent Tissue-Based Biomarkers in Endometrioid Endometrial Cancer: Tumor Budding in Microsatellite Instability and WHO Grading in Copy-Number-Low Patients.

Stogbauer F, Gess B, Brambs C, Lautizi M, Kacprowski T, Ourailidis I Cancers (Basel). 2023; 15(15).

PMID: 37568650 PMC: 10416921. DOI: 10.3390/cancers15153832.


Immune Environment and Immunotherapy in Endometrial Carcinoma and Cervical Tumors.

Laine A, Gonzalez-Lopez A, Hasan U, Ohkuma R, Ray-Coquard I Cancers (Basel). 2023; 15(7).

PMID: 37046702 PMC: 10093320. DOI: 10.3390/cancers15072042.

References
1.
Vermij L, Smit V, Nout R, Bosse T . Incorporation of molecular characteristics into endometrial cancer management. Histopathology. 2019; 76(1):52-63. PMC: 6972558. DOI: 10.1111/his.14015. View

2.
Guasti L, Sze W, McKay T, Grose R, King P . FGF signalling through Fgfr2 isoform IIIb regulates adrenal cortex development. Mol Cell Endocrinol. 2013; 371(1-2):182-8. PMC: 3650577. DOI: 10.1016/j.mce.2013.01.014. View

3.
Haase M, Thiel A, Scholl U, Ashmawy H, Schott M, Ehlers M . Subcellular localization of fibroblast growth factor receptor type 2 and correlation with CTNNB1 genotype in adrenocortical carcinoma. BMC Res Notes. 2020; 13(1):282. PMC: 7288682. DOI: 10.1186/s13104-020-05110-5. View

4.
Colas E, Pedrola N, Devis L, Ertekin T, Campoy I, Martinez E . The EMT signaling pathways in endometrial carcinoma. Clin Transl Oncol. 2012; 14(10):715-20. DOI: 10.1007/s12094-012-0866-3. View

5.
Mayakonda A, Lin D, Assenov Y, Plass C, Koeffler H . Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018; 28(11):1747-1756. PMC: 6211645. DOI: 10.1101/gr.239244.118. View